KPTI News and Press, Karyopharm Therapeutics Inc. From 02/13/20

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2019 Q4 earnings Read more ...

Karyopharm Therapeutics (NASDAQ: KPTI ): Q4 GAAP EPS of -$0.76 misses by $0.08 . More news on: Karyopharm Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- XPOVIO Net Product Sales of $17.7 Million for Fourth Quarter and $30.5 Million for Full Year 2019 -- -- XPOVIO Prescription Demand Increased by 65% in Fourth Quarter 2019 Compared to Third Quarter 2019 -- -- sNDA for Selinexor in DLBCL Submitted to FD...

Karyopharm Therapeutics (NASDAQ: KPTI ) and Promedico, a member of the Neopharm Group, have entered into an exclusive distribution agreement for the commercialization of XPOVIO (selinexor), Karyopharm’s lead SINE compound, in Israel and the Palestinian Authority. More news on...

NEWTON, Mass. and PETAH TIKVA, Israel, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, and Promedico, a member of the Neopharm Group, today announced their entry into an exclusive distribution agreement for the commer...

NEWTON, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report fourth quarter and full year 2019 financial results on Thursday, February 13, 2020. Karyopharm's management team will ...

Healthcare Pulse The market doesn't like uncertainty. And when you think about healthcare, that uncertainty is immediately magnified. Fundamentally, healthcare couldn't be better positioned, with an aging America, rapidly advancing therapies, a faster-moving FDA, easy access to risk capi...

Biogen (NASDAQ: BIIB) shocked investors last year when it said it would submit its investigational Alzheimer's drug to the Food and Drug Administration for approval -- months after halting studies that showed the drug didn't work. The biotech company explained its decision to file in early&...

Source: GraycellAdvisors.com Systematic Investing Systematic investing has become a growing part of the stock market. The investing style refers to a rules-based algorithmic system that limits or eliminates individual judgments and biases towards portfolio selection and adjustments. ...

Amedisys (NASDAQ: AMED ) initiated with Outperform rating and $206 (14% upside) price target at Credit Suisse. More news on: Amedisys, Inc., BeiGene, Ltd., Karyopharm Therapeutics Inc., Healthcare stocks news, , Read more ...